Ken Griffin
JANX icon

Ken Griffin’s Janux Therapeutics JANX Stock Holding History

Ken Griffin’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$605K Sell
43,500
-40,300
-48% -$553K ﹤0.01% 8834
2025
Q4 		$1.16M Buy
83,800
+69,300
+478% +$1.63M ﹤0.01% 7073
2025
Q3 		$354K Sell
14,500
-3,900
-21% -$95K ﹤0.01% 9963
2025
Q2 		$425K Buy
18,400
+1,700
+10% +$44.8K ﹤0.01% 9013
2025
Q1 		$451K Sell
16,700
-19,300
-54% -$728K ﹤0.01% 8701
2024
Q4 		$1.93M Sell
36,000
-15,100
-30% -$799K ﹤0.01% 5712
2024
Q3 		$2.32M Buy
51,100
+21,700
+74% +$944K ﹤0.01% 5253
2024
Q2 		$1.23M Sell
29,400
-22,600
-43% -$1.06M ﹤0.01% 6194
2024
Q1 		$1.96M Buy
52,000
+51,300
+7,329% +$1.12M ﹤0.01% 5564
2023
Q4 		$7.51K Buy
700
+300
+75% +$2.59K ﹤0.01% 13284
2023
Q3 		$4.03K Sell
400
-1,000
-71% -$11.5K ﹤0.01% 13523
2023
Q2 		$16.6K Sell
1,400
-700
-33% -$9.36K ﹤0.01% 12891
2023
Q1 		$25.4K Buy
2,100
+500
+31% +$8.32K ﹤0.01% 12873
2022
Q4 		$21.1K Buy
+1,600
New +$23.4K ﹤0.01% 13109

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ken Griffin's JANX Position: Q1 2026 in Review

Ken Griffin reduced its Janux Therapeutics (JANX) stake by 68% in Q1 2026, selling an estimated $10.3M and leaving 352,177 shares worth $4.9M. The position accounts for ﹤0.01% of the portfolio, ranked #4370.

Ken Griffin first reported a position in JANX in Q2 2021 and has held it in 20 quarters since. The position peaked at $88.5M in Q1 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Ken Griffin held 352,177 shares of Janux Therapeutics worth $4.9M as of Q1 2026.
  • Ken Griffin sold 751,967 Janux Therapeutics shares in Q1 2026, an estimated $10.3M.
  • Janux Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4370 holding.
  • Ken Griffin first reported a position in Janux Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Ken Griffin's Janux Therapeutics position peaked at $88.5M in Q1 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.